Carvajal Francisca, Herrera Karin, Núñez Paulina, Flores Lilian, Córdova Andrea, Pizarro Gonzalo, San Martín Pamela, Contreras Luis, Quera Rodrigo
Universidad de los Andes, Centro Enfermedades Digestivas, Programa de Enfermedad Inflamatoria Intestinal, Clínica Universidad de los Andes, Santiago, Chile.
Universidad de los Andes, Centro Enfermedades Digestivas, Programa de Enfermedad Inflamatoria Intestinal, Clínica Universidad de los Andes, Santiago, Chile; Área de Investigación, Clínica Universidad de los Andes, Santiago, Chile; Programa de Nutrición y Ciencia de los Alimentos, Universidad de Granada, Granada, España.
Gastroenterol Hepatol. 2025 Aug-Sep;48(7):502437. doi: 10.1016/j.gastrohep.2025.502437. Epub 2025 Mar 25.
In ulcerative colitis (UC), STRIDE-II consensus has established the long-term goal of achieving endoscopic remission (ER), which helps reduce inflammatory burden, prevent permanent intestinal damage, and improve patient's quality of life. However, achieving histological remission (HR) is also associated with a lower risk of experiencing outbreaks of inflammatory activity, the need for corticosteroids, hospitalizations, and the development of colorectal cancer.
Evaluate the role of ER and HR in the development of inflammatory activity flares in patients who have achieved these long-term goals and are being followed in the Inflammatory Bowel Disease (IBD) Program.
A retrospective study was conducted on patients with UC treated in the IBD Program at the Universidad de los Andes, between January 2021 and April 2023. Patients with ER (Mayo Endoscopic Index [MEI] 0) or endoscopic response (MEI 1), with at least one year of follow-up, were included. HR was defined using the Nancy (<2), Geboes (<2), and Robarts (<3) indices. Inflammatory activity was assessed by a Partial Mayo Index (PMI) ≥2 and fecal calprotectin >250μg/g.
A total of 84 patients were included, 57.1% were women, with a median age of 37 years (IQR 31-45). During follow-up, 71 patients continued in the study, and 24 (31%) experienced inflammatory flares. In the MEI 0 group, the percentage of flares at 12 and 44 months was 15% and 53%, respectively, compared to 43% and 67% in the MEI 1 group (p=0.0302). PMI and fecal calprotectin levels were significantly lower in MEI 0 than in MEI 1 (p<0.001 and p<0.05, respectively). Although the Nancy, Geboes, and Robarts indices showed significant differences between MEI 0 and MEI 1, none were associated with a lower risk of flares in the MEI 0 group. No cases of colorectal neoplasia or need for surgery were reported during follow-up.
In this cohort, ER is a significant predictor of the development of inflammatory flares in patients with UC, while HR did not show a clear impact in this regard. Further studies are needed to clarify the role of HR as a therapeutic target in UC.
在溃疡性结肠炎(UC)中,STRIDE-II共识确立了实现内镜缓解(ER)的长期目标,这有助于减轻炎症负担、预防永久性肠道损伤并改善患者生活质量。然而,实现组织学缓解(HR)也与炎症活动爆发风险降低、使用皮质类固醇的必要性、住院率以及结直肠癌的发生相关。
评估ER和HR在已实现这些长期目标并在炎症性肠病(IBD)项目中接受随访的患者炎症活动发作发展中的作用。
对2021年1月至2023年4月在安第斯大学IBD项目中接受治疗的UC患者进行回顾性研究。纳入达到ER(梅奥内镜指数[MEI]为0)或内镜缓解(MEI为1)且至少随访一年的患者。HR使用南希(<2)、格博斯(<2)和罗伯茨(<3)指数进行定义。炎症活动通过部分梅奥指数(PMI)≥2和粪便钙卫蛋白>250μg/g进行评估。
共纳入84例患者,57.1%为女性,中位年龄为37岁(四分位间距31 - 45岁)。在随访期间,71例患者继续参与研究,24例(31%)经历了炎症发作。在MEI为0的组中,12个月和44个月时发作的百分比分别为15%和53%,而MEI为1的组中分别为43%和67%(p = 0.0302)。MEI为0时PMI和粪便钙卫蛋白水平显著低于MEI为1时(分别为p<0.001和p<0.05)。尽管南希、格博斯和罗伯茨指数在MEI为0和MEI为1之间显示出显著差异,但在MEI为0的组中均未显示与发作风险降低相关。随访期间未报告结直肠肿瘤病例或手术需求。
在该队列中,ER是UC患者炎症发作发展的重要预测指标,而HR在这方面未显示出明显影响。需要进一步研究以阐明HR作为UC治疗靶点的作用。